6533b838fe1ef96bd12a47d0
RESEARCH PRODUCT
Effect of intravenous flecainide on atrial vulnerability in man.
Norbert TreeseWolfgang KasperJ. C. KangThomas MeinertzTiberius Popsubject
AdultMalemedicine.medical_specialtyAdolescentRefractory periodBody weightElectrocardiographyBolus (medicine)PiperidinesHeart Conduction SystemInternal medicineDrug DiscoveryAtrial FibrillationmedicineHumanscardiovascular diseasesFlecainideGenetics (clinical)AgedFlecainidebusiness.industryAtrial vulnerabilityEffective refractory periodCardiac Pacing ArtificialGeneral MedicineAtrial arrhythmiasMiddle Agedmedicine.anatomical_structureAtrial Fluttercardiovascular systemCardiologyMolecular MedicineRight atriumFemalebusinessAnti-Arrhythmia Agentsmedicine.drugdescription
Sixteen patients were investigated by means of programmed atrial stimulation at two different driving rates: 100 and 120/min. All patients had an increased atrial vulnerability at both driving rates. After intravenous flecainide application (1 mg/kg body weight as a bolus followed by the same amount given by infusion over a period of 20 min) the increased vulnerability was abolished in 11 and 9 patients respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a significant shortening of the relative refractory period of the right atrium. It is concluded that flecainide may be effective in the treatment of atrial arrhythmias in man.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1983-06-15 | Klinische Wochenschrift |